According to GW Pharmaceuticals’ Q1 sales report, Epidiolex sales brought in $33.five million amongst January and March 2019.
Final year, Epidiolex became the initial weed-derived pharmaceutical authorized by the US FDA. The drug’s active ingredient is CBD, and it is only authorized for hard-to-treat seizure issues, such as Dravet syndrome and Lennox-Gastaut syndrome. On the other hand, medical doctors may well quickly be in a position to prescribe it for tubular sclerosis, as effectively, if it passes Phase III clinical trials for the certain situation.
Presently, there are more than 7,600 sufferers in the US with Epidiolex prescriptions, issued by more than 1,900 medical doctors. GW Pharma announced it would quickly make the CBD drug obtainable in European markets, as well.
Epidiolex’s surprising good results prompted 1 advertising and marketing firm to credit the drug’s FDA approval for the international CBD market’s speedy development. Reports and Information estimated, worldwide, CBD goods could garner up to $16 billion in sales by 2026. The firm stated today’s CBD sector is worth about $1.four billion.
Other advertising and marketing analyses predict a a great deal brighter future for CBD, with estimates reaching $22 billion in sales as early as 2022.
GW Pharma and its American subsidiary, Greenwich Biosciences, has caught flak for the cost of its potentially blockbuster drug. A year’s worth of Epidiolex fees $32,500, substantially a lot more than most non-FDA-authorized CBD oils obtainable at marijuana retail shops and healthcare dispensaries.
In 2017, GW Pharma’s CEO, Justin Gover, told MERRY JANE that the corporation differs from other CBD suppliers mainly because it gives a precisely dosed pharmaceutical formulation of the well known cannabinoid. Current research have shown that some CBD goods include risky adulterants, and some do not even include CBD at all.
Epidiolex’s FDA approval tends to make the drug legal everywhere in the US with a prescription, even in states that prohibit healthcare marijuana. Federal marijuana prohibition has kept other CBD goods stuck in a legal gray region, as some states tolerate them and other folks do not.
Stick to Randy Robinson on Twitter